Alnylam Pharmaceuticals vs Argenx
Alnylam Pharmaceuticals and Argenx are similar in size: $3.71bn and $4.15bn of revenue in their latest fiscal years. Argenx grew faster (89.9% against 65.2%). Argenx kept more of each dollar of sales as profit: a net margin of 31.1% against 8.4%. Argenx carries less debt relative to equity (0.0% against 127.7%).
| Latest fiscal year | Alnylam PharmaceuticalsALNY, 2025 | ArgenxARGX, 2025 |
|---|---|---|
| Revenue | $3.71bn | $4.15bn |
| Revenue growth | 65.2% | 89.9% |
| Net income | $314m | $1.29bn |
| Operating margin | 13.5% | 25.4% |
| Net margin | 8.4% | 31.1% |
| Return on equity | 73.3% | 20.2% |
| Free cash flow | $465m | $679m |
| Cash | $1.66bn | $3.49bn |
| Total debt | $1.01bn | $0 |
| Debt to equity | 127.7% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 2,500 | — |
| Market value | $21.46bn | $55.65bn |
| Price vs our value range | Above our value range | — |
| Moat score | 33 (Weak) | — |
| Insider trades, 12 months | 0 buys, 279 sales | 0 buys, 0 sales |